Recombinant Proteins Market To Reach $5.58 Billion By 2030

Recombinant Proteins Market Growth & Trends

The global recombinant proteins market size is expected to reach USD 5.58 billion in 2030 and is projected to grow at a CAGR of 10.2% from 2025 to 2030. Diseases like multiple sclerosis, neutropenia, cerebral apoplexy, anemia, and others, as well as dwarfism, are becoming more common, which is driving up the demand for recombinant protein drugs. Furthermore, the industry is anticipated to expand due to the increased development and research on biologics, which, in turn, are significantly boosting global industry growth. The focus on the development of biosimilars, biologics, and recombinant proteins has increased owing to a rise in the incidence and prevalence of cancer and the expansion of research & development activity.

According to the American Cancer Society, in 2022, there will be 1.9 million new cancer cases and 609,360 cancer-related deaths. In addition, the expanding application of recombinant proteins in clinical diagnostic methods including ELISA, Western Blotting, and Immunohistochemistry (IHC) is anticipated to fuel market expansion. Due to factors including rising R&D spending, an increase in the number of cancer patients, and the desire for novel & tailored therapies, the global industry is anticipated to expand significantly during the forecast period. Research activity in recombinant protein space has increased in response to the COVID-19 pandemic as a result of efforts to comprehend the dynamics of the virus. The production of recombinant proteins has increased significantly, along with tailored treatment.

In addition, research funding is predicted to become more readily available along with an increase in demand for and production of recombinant proteins, particularly those immune response proteins associated with COVID-19. Therefore, positive effects have been seen for the companies offering products specifically made for COVID-19. Recombinant protein is viewed as a modified version of natural protein that can be produced in a number of ways to improve protein output, create useful commercial goods, and alter gene sequences. The main drivers of the global industry are the rise in pharmaceutical firms’ R&D expenditures, high incidence of chronic illnesses, an increase in the number of regulatory requirements, and the ongoing need to reduce viral infections.

Over the projected period, the global industry is anticipated to be driven by technological advancements in the synthesis of recombinant proteins. For instance, in June 2022, according to the data produced by the National Center for Biotechnology Information, new breeding techniques, such as CRISPR/Cas9, TALEN, and Zinc Finger mediated, as well as transgenic or cis-genic techniques, are emerging technologies that may make it easier for in vitro genetic editing or manipulation of the genes to be approved. In addition, industry participants are anticipated to invest in the region due to the aging population, rising income levels, better healthcare infrastructure, rising healthcare spending, and the advantages of low-cost manufacturing in developing nations, thereby propelling market growth.

 Request a free sample copy or view report summary: Recombinant Proteins Market Report

Recombinant Proteins Market Report Highlights

• The cytokines & growth factors segment held the largest share of 24.6% of the market in 2024. This segment is anticipated to grow exponentially throughout the forecast period.

• The therapeutics segment dominated the global market with a share of 34.2% in 2024 due to the prevalence of various diseases, such as metabolic disorders, cancer, genetic disorders, and immune diseases.

• The pharma & biotechnology companies segment captured the largest market share of 38.1% in 2024. The inclination towards biologics and biosimilars has resulted in a cascade of multi-million investments by bio-manufacturers in R&D to grow the pipeline of products, devise new technologies, and advance bioprocessing tools.

• The mammalian segment held the largest revenue share of 42.1% of the recombinant proteins market in 2024.

• North America was the dominant region in 2024 due to an increase in the incidence of chronic diseases, use of cutting-edge treatments, the presence of key players, and a rise in healthcare spending in the region.

Recombinant Proteins Market Segmentation

Grand View Research has segmented the global recombinant proteins market based on product, application, end use, host cell, and region:

Recombinant Proteins Product Outlook (Revenue, USD Million, 2018 - 2030)

• Cytokines & Growth Factors

  • Interferons (IFNs)

  • Interleukins (ILs)

  • Others

• Antibodies

• Immune checkpoint proteins

• Virus Antigens

• Enzymes

  • Kinases

  • Metabolic enzymes

  • Others

• Recombinant Regulatory Protein

• Hormones

• Others

Recombinant Proteins Application Outlook (Revenue, USD Million, 2018 - 2030)

• Drug Discovery & Development

• Therapeutics

  • Biologics

  • Vaccines

  • Cell & Gene Therapies

  • Others

• Research

• Others

Recombinant Proteins End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharma & Biotechnology Companies

• Academic & Research Institutes

• Diagnostic Laboratories

• Others

Recombinant Proteins Host Cell Outlook (Revenue, USD Million, 2018 - 2030)

• Mammalian systems

• Insect Cells

• Yeast & Fungi

• Bacterial Cells

• Others

Recombinant Proteins Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of the Recombinant Proteins Market

• Sino Biological, Inc.

• Bio-Techne

• GenScript

• Bio-Rad Laboratories, Inc.

• Merck KGaA

• Thermo Fisher Scientific

• Proteintech Group, Inc.

• Enzo Life Sciences, Inc. 

• Abnova Corporation

• RayBiotech Life Inc.

• STEMCELL Technologies Inc.